1. Home
  2. MGNX vs MFIN Comparison

MGNX vs MFIN Comparison

Compare MGNX & MFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.20

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Logo Medallion Financial Corp.

MFIN

Medallion Financial Corp.

HOLD

Current Price

$9.57

Market Cap

232.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNX
MFIN
Founded
2000
1995
Country
United States
United States
Employees
N/A
179
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
220.6M
232.1M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
MGNX
MFIN
Price
$4.20
$9.57
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$5.00
$12.00
AVG Volume (30 Days)
1.3M
54.4K
Earning Date
05-08-2026
04-29-2026
Dividend Yield
N/A
5.18%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$149,500,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.19
$0.02
P/E Ratio
N/A
$6.21
Revenue Growth
N/A
N/A
52 Week Low
$1.19
$7.85
52 Week High
$4.64
$11.00

Technical Indicators

Market Signals
Indicator
MGNX
MFIN
Relative Strength Index (RSI) 58.58 51.36
Support Level $1.49 $9.15
Resistance Level $4.64 $9.87
Average True Range (ATR) 0.30 0.31
MACD -0.03 0.01
Stochastic Oscillator 60.50 46.15

Price Performance

Historical Comparison
MGNX
MFIN

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

About MFIN Medallion Financial Corp.

Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.

Share on Social Networks: